REpAb® Direct-from-Patient Human Antibody Discovery.
Unlock the full potential of naturally occurring human antibodies with REpAb®.
Antibody Discovery From Your Patients.
How It Works.
By combining affinity-purified polyclonal IgG with mass spectrometry and Ig-sequencing, REpAb® reconstructs monoclonal antibodies that reflect the true, affinity-matured humoral response in patients. REpAb® is a proprietary platform for direct-from-patient human antibody discovery, enabling researchers to access the functional diversity of circulating antibodies without relying on B cell isolation.
Why antibody discovery directly from patients?
Circulating human IgG represents a highly information-dense and functionally validated record of immune experience, yet it is largely ignored by conventional proteomics and antibody discovery approaches. REpAb® addresses this gap by directly interrogating antigen-specific IgG from human serum. Through targeted enrichment and de novo sequencing, REpAb® enables recovery of full antibody sequences that retain native affinity, specificity, and function. This platform transforms the circulating Ig-ome into a scalable source of fully human, in vivo validated therapeutic and diagnostic antibodies.
REpAb® Platform Capabilities.
Application Note: Discovery of Neutralizing Antibodies from Human Patients
Traditional antibody discovery methods often only rely on B-cell sequencing, which may not fully represent the circulating serum antibodies responsible for immune protection. In this study, Rapid Novor researchers applied a proteomics-driven approach to directly sequence antigen-specific polyclonal IgG from human plasma following SARS-CoV-2 vaccination, enabling recovery of functional antibodies that are missed by B-cell–based workflows.
Twelve of the identified heavy and light chain sequences were recombinantly expressed and evaluated. Half demonstrated strong antigen binding comparable to or exceeding native polyclonal reference as well as functional neutralization activity, confirming biological relevance.
Direct serum sequencing revealed antibodies absent from B cell datasets, underscoring the value of proteomics-based discovery.
Getting Started.
Deliverables
- Full-length, antigen-specific monoclonal antibody sequences with confidence metrics through peptide datasets.
- Abundance and ranking data to prioritize leads.
- Technical report summarizing methods, results, and recommended candidates.
- Recombinant expression constructs and expression data (optional).
- Biophysical characterization of recombinant antibodies (optional).
Turn-Around Time
1. Affinity Purification of Antigen-Specific IgG
The REpAb® workflow begins with enrichment of antibodies directly from patient plasma or serum. Using highly specific antigen probes, polyclonal IgG is captured from the complex plasma mixture, ensuring that only antibodies with functional relevance to the target antigen are analyzed. This approach isolates naturally affinity-matured antibodies without the need for B cell sorting, capturing the true physiological repertoire of circulating antibodies.
2. De Novo Mass Spectrometry Sequencing
Affinity-purified IgG undergoes high-resolution mass spectrometry, enabling de novo sequencing of peptides through our proprietary software. This allows REpAb® to reconstruct the amino acid sequences of individual monoclonal antibodies from complex polyclonal pools, even when the heavy and light chain pairing is not initially known.
Key capabilities include:
- Identification of CDR, framework, and constant region amino acid sequences.
- Reconstruction of complete monoclonal antibody sequences, including heavy and light chain pairing.
- Cross-references MS data with Ig-sequencing, prioritizing high-confidence sequences.
3. Recombinant Expression and Functional Validation
Identified monoclonal antibody protein sequences are recombinantly expressed and evaluated for functional relevance:
- ELISA or other binding assays to confirm target specificity.
- Ranking of candidates by abundance, sequence quality, or functional metrics.
4. Biophysical Characterization
To support lead selection and downstream development, we integrate:
- Surface Plasmon Resonance (SPR)
- Epitope Binning (through SPR or AI assisted)
- Hydrogen-Deuterium Exchange Mass Spectrometry (HDX-MS)
Talk to Our Scientists.
We Have Sequenced 9000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics
Talk to our scientists. We have sequenced over 9000+ antibodies and we are eager to help you.
Talk to Our Scientists.
Antibody Discovery, Directly.
The most direct route to a functional antibody starts with a functional mixture of antibodies, not just cells or sequences. Contact us.
The Science of Antibody Discovery.
Antibody Sequencing & Discovery Services.
Antibody Sequencing, Discovery and Characterization Services.
Antibody Sequencing & Discovery Services.
REmAb® mAb Sequencing
Monoclonal antibody sequencing from small antibody samples, no need for hybridoma or DNA information. Full sequence in record time.
Explore Antibody Sequencing Services
REpAb® pAb Sequencing
Polyclonal antibody sequencing and antibody discovery service. Sequence antibodies from blood or a polyclonal mixture.
Explore Antibody Discovery Services
RapidSPR™ Analysis
Label-free evaluation of antibody-antigen binding using surface plasmon resonance on Biacore or Nicoya. Can be employed for detailed kinetic profiling, kinetics screening, or epitope binning.
Explore SPR Services
RapidHDX-MS™
Mass spec based epitope mapping. Epitope mapping for identify the binding site of an antibody to its corresponding antigen with the highest confidence and resolution.
Explore HDX-MS Epitope Mapping Service
MATCHmAb™
Antibody verification by rapid peptide mapping. Antibody sequence confirmation and full detailed mapping for development purposes.
Explore Peptide Mapping Service
Antibody Characterization
LC-MS analysis for study of antibody glycosylation, disulfide bonds, post-translational modifications, sequence variants, intact mass and size.
Explore Antibody Characterization Services